Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer

Benjamin Schneider, Sébastien Benzekry, Jonathan Mochel

First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to the…